Maribel Health, a company that helps healthcare systems design, build and operate technology-enabled home and community clinical care services, secured $25 million in a Series A funding round led by General Catalyst.
The New Hampshire-based company was launched as part of General Catalyst’s “hatch” program, where the venture capital firm provides resources to start companies from the ground up then works with them as they grow.
Maribel Health offers clinical workflows, training, technology, operating capacity and automation for remote clinical care teams as an extension of a health system or outpatient clinic.
The company also announced partnerships with St. Louis-based Mercy Health System and New Jersey-based BAYADA Home Health Care, in which Maribel will design, develop and manage hospital-at-home programs that will ultimately be the base for other home care models.
The funds will be used to speed up growth with the company’s existing partners, onboard new talent and further develop its technology platform.
“Together, with our shared Health Assurance vision, we built Maribel: a technology-enabled operating partner on a mission to work within health systems to integrate advanced home and community-based care,” Hemant Taneja, CEO and managing director of General Catalyst, said in a statement.
“Maribel is the most recent hatch company that leveraged GC’s Creation Strategy, joining our early successes in company-building, namely Livongo, Commure, Kayak and Homeward. We believe this paradigm shift toward meeting people where they are will improve the quality of care and increase the total health system capacity.”
Dublin-based connected medical device company Fire1 closed a $25 million financing round led by Andera Partners and Novo Holdings.
The round also included existing investors Gilde Healthcare, the Ireland Strategic Investment Fund, New Enterprise Associates, Lightstone Ventures, Gimv, Medtronic and Seventure Partners.
Aneta Sottil, director at Andera Life Sciences, and Eric Snyder, partner of venture investments at Novo Holdings, will join the company’s board of directors.
The company offers an implant that allows for remote monitoring of patients with heart failure. Fire1 will use the funds to accelerate the development of its remote monitoring solution.
Protai, an AI-enabled drug discovery platform, announced it had added $12 million to its seed funding, bringing the total amount raised to $20 million.
Existing investors Grove Ventures and Pitango HealthTech participated in the round alongside Copenhagen-based Maj Invest Equity Fund.
The Israeli company analyzes protein-level biomarkers using its proteomics AI-based platform to map the course of a disease to help researchers discover drugs and predict which patients will respond to a given drug.
The company will use the additional funds to build its oncology drug discovery pipeline, increase its activities through pharma partnerships and swell its data acquisition.
The funds add to the company’s $8 million seed funding received in 2022.
Salim Ismail will offer more detail at his HIMSS23 presentation “Executive Summit Keynote: Disruptive Convergence.” It is scheduled for Monday, April 17, at 3:45 – 4:30 p.m. CT at the Marriott Marquis Chicago, Level 4, in the Grand Horizon Ballroom.